LNC Therapeutics, a French biotech company specialising in research and development for gut microbiome-based drugs, announces the appointment of Dr Georges Rawadi as its new CEO.
Prior to joining LNC Therapeutics, Georges Rawadi, formerly a researcher at Institut Pasteur, was VP of Business Development & Intellectual Property and a member of the management team at Celyad. Previously, he successfully held various business development positions at Cellectis, Galapagos, ProStrakan and Sanofi-Aventis and led strategic alliance development consulting assignments.
He holds a PhD in Microbiology from Pierre and Marie Curie University (France) and a Master's degree in Management and Strategy in the Health Industry from ESSEC Business School.
LNC Therapeutics' main objective is to develop new drug candidates with a mechanism of action based on microbiome interaction with gut. Targeted therapeutic indications are pathologies caused by metabolic or immune system deregulation.
"The innovations resulting from our understanding of the microbiome are still in their infancy, and I am very proud to lead LNC Therapeutics' ambitions in this field," said Dr Rawadi.
Everything that has been accomplished so far, the result of collaborative work led by Sandrine Claus and the founding team, is a solid basis for exploring new ways of developing breakthrough therapies based on gut microbiome mechanisms. While the treatment of obesity and cardiometabolic diseases remain our first indications, we are now convinced that our work will enable us to expand to other therapeutic areas, and particularly towards severe diseases that still have no or limited effective treatment.